Get the Stockscreener App
3.075
7.50%
-0.2492
After Hours:
3.08
0.005
+0.16%
Reshape Lifesciences Inc stock is traded at $3.075, with a volume of 76,470.
It is down -7.50% in the last 24 hours and down -36.73% over the past month.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
See More
Previous Close:
$3.3242
Open:
$3.32
24h Volume:
76,470
Relative Volume:
1.19
Market Cap:
$2.24M
Revenue:
$9.81M
Net Income/Loss:
$-26.16M
P/E Ratio:
-0.0793
EPS:
-38.77
Net Cash Flow:
$-17.45M
1W Performance:
-18.44%
1M Performance:
-36.73%
6M Performance:
-70.72%
1Y Performance:
-72.74%
1-Day Range:
$2.90
$3.3633
1-Week Range:
$2.90
$3.92
52-Week Range:
$2.90
$29.00
Reshape Lifesciences Inc Stock (RSLS) Company Profile
Name
Reshape Lifesciences Inc
Sector
Industry
Phone
949-429-6680
Address
1001 CALLE AMANECER, SAN CLEMENTE
Compare RSLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RSLS
Reshape Lifesciences Inc
|
3.075 | 2.24M | 9.81M | -26.16M | -17.45M | -38.77 |
|
ABT
Abbott Laboratories
|
128.22 | 222.39B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.02 | 154.78B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
396.07 | 150.99B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.82 | 116.46B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
70.99 | 41.87B | 6.60B | 4.16B | 490.10M | 6.93 |
Reshape Lifesciences Inc Stock (RSLS) Latest News
Accuray (ARAY) Stock Surges Amidst Market Activity - GuruFocus.com
ReShape Lifesciences receives international patent in Israel for its proprietary diabetes neuromodulation technology; shares rise - MSN
ReShape Lifesciences secures key diabetes treatment patent - MSN
ReShape Lifesciences® Granted Key International Patent in - GlobeNewswire
ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology - Yahoo Finance
Bariatric Surgery Market to Surpass USD 3.34 Billion by 2032, Growing at a CAGR of 7.85% - EIN News
Electroceutical Devices Market Projected To Witness Massive Growth, 2025-2032 | Medtronic plc, Abbott Laboratories - openPR
Bariatric Surgery Devices Market: Robust Growth, Key Players, and Future Trends - openPR
RSLS Stock Touches 52-Week Low at $4.07 Amid Market Challenges By Investing.com - Investing.com South Africa
RSLS Stock Touches 52-Week Low at $4.07 Amid Market Challenges - Investing.com India
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates LBRDA, OMIC, NEUE, RSLS on Behalf of Shareholders - The Malaysian Reserve
$TOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the MergerRSLS, TURN, RDW, NEUE - Markets Insider
ReShape Lifesciences amends convertible note terms with investor By Investing.com - Investing.com Australia
ReShape Lifesciences amends convertible note terms with investor - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GLXZ, R - GuruFocus.com
ReShape Lifesciences updates on merger with Vyome Therapeutics - TipRanks
ReShape and Vyome to merge in all-stock deal By Investing.com - Investing.com Australia
ReShape and Vyome to merge in all-stock deal - Investing.com
ReShape Lifesciences® Provides Update on Merger Agreement - GlobeNewswire
ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys - Yahoo Finance
ReShape Lifesciences Merges with Vyome, Sells Core Medical Device Portfolio to Biorad - StockTitan
Obesity Treatment Market is Booming Worldwide | Pfizer, Nutrisystem, Roche, - openPR
Rising Burden of Neurological Disorders in Emerging Economies Fuels Demand for Vagus Nerve Stimulation Therapy - PharmiWeb.com
Vagus Nerve Stimulators Market Growth in Future Scope 2024-2031 - openPR
Global Bariatric Surgery Devices Market Set For 9.3% Growth, Reaching $2.98 Billion By 2028 - NEWS CHANNEL NEBRASKA
Synthetic Biosensors Market Set to Witness Steady Growth through (2024-2031) - WhaTech
RSLS Stock Touches 52-Week Low at $4.48 Amid Market Challenges By Investing.com - Investing.com South Africa
ReShape Lifesciences Announces Merger and Asset Sale Plans - TipRanks
RSLS Stock Touches 52-Week Low at $4.48 Amid Market Challenges - Investing.com
Bariatric Surgery Devices Market is expected to grow at a CAGR - openPR
ReShape Lifesciences faces Nasdaq delisting over equity shortfall - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENV, RS - GuruFocus.com
Bariatric Surgery Devices Market Global Forecasts Report and Company Analysis 2025-2033, Featuring Apollo Endosurgery, GI Dynamics, Intuitive Surgical, J&J, Medtronic, Olympus, Reshape, TransEnterix - GlobeNewswire
Weight-Loss Devices Market Will Drive an Exponential CAGR - openPR
Intragastric Balloons Market Size to Surpass USD 160.7 - GlobeNewswire
Earnings call: ReShape Lifesciences reports growth and strategic mergers - Investing.com
Earnings call: ReShape Lifesciences reports growth and strategic mergers By Investing.com - Investing.com Canada
ReShape Lifesciences Inc (RSLS) Quarterly 10-Q Report - Quartzy
ReShape Lifesciences Reports Q3 Growth and Strategic Moves - TipRanks
ReShape Lifesciences® Reports Third Quarter Ended September - GlobeNewswire
ReShape Lifesciences Reports 16.6% Revenue Growth, Inks $5.16M Asset Sale Deal | RSLS Stock News - StockTitan
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update - The Manila Times
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and - The Bakersfield Californian
Gastric Electrical Stimulators Market Size, Share and Growth - openPR
Health Canada approves ReShape's Lap-Band 2.0 FLEX By Investing.com - Investing.com Australia
FibroGen Reports Third Quarter 2024 Financial Results - The Manila Times
ReShape Lifesciences® to Announce Financial Results for the - GlobeNewswire
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - The Manila Times
ReShape Lifesciences (RSLS) Sets Q3 2024 Earnings Call with Post-Merger Chairman | RSLS Stock News - StockTitan
ReShape secures NIH grant to develop electrodes for diabetes treatment device - Medical Device Network
Health Canada approves ReShape's Lap-Band 2.0 FLEX - Investing.com
Reshape Lifesciences Inc Stock (RSLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.14%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):